Related Citations for PubMed (Select 20181064) - PubMed - NCBI

Warning: The NCBI web site requires JavaScript to function. more...

My NCBI Sign In

<< First< Prev

Page of 5

Results: 1 to 20 of 93

1.

High Erk activity suppresses expression of the cell cycle inhibitor p27Kip1 in colorectal cancer cells.

Kress TR, Raabe T, Feller SM.

Cell Commun Signal. 2010 Feb 2;8(1):1.

PMID:: 20181064; [PubMed]

Related citations

2.

Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.

Gysin S, Lee SH, Dean NM, McMahon M.

Cancer Res. 2005 Jun 1;65(11):4870-80.

PMID:: 15930308; [PubMed - indexed for MEDLINE]

Related citations

3.

Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.

Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R.

Int J Oncol. 2004 Mar;24(3):591-608.

PMID:: 14767544; [PubMed - indexed for MEDLINE]

Related citations

4.

Noncatalytic function of ERK1/2 can promote Raf/MEK/ERK-mediated growth arrest signaling.

Hong SK, Yoon S, Moelling C, Arthan D, Park JI.

J Biol Chem. 2009 Nov 27;284(48):33006-18. Epub 2009 Oct 5.

PMID:: 19805545; [PubMed - indexed for MEDLINE]

Free PMC Article

Related citations

5.

Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression.

Yip-Schneider MT, Lin A, Barnard D, Sweeney CJ, Marshall MS.

Int J Oncol. 1999 Aug;15(2):271-9.

PMID:: 10402237; [PubMed - indexed for MEDLINE]

Related citations

6.

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.

Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, Sandler RS, Kim HJ, Keku TO, Der CJ.

Mol Cancer Ther. 2009 Apr;8(4):834-43.

PMID:: 19372556; [PubMed - indexed for MEDLINE]

Free PMC Article

Related citations

7.

Down-regulation of Cdx2 in colorectal carcinoma cells by the Raf-MEK-ERK 1/2 pathway.

Krueger F, Madeja Z, Hemberger M, McMahon M, Cook SJ, Gaunt SJ.

Cell Signal. 2009 Dec;21(12):1846-56. Epub 2009 Aug 14.

PMID:: 19686845; [PubMed - indexed for MEDLINE]

Related citations

8.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:: 16854453; [PubMed - indexed for MEDLINE]

Related citations

9.

Magnolol elicits activation of the extracellular signal-regulated kinase pathway by inducing p27KIP1-mediated G2/M-phase cell cycle arrest in human urinary bladder cancer 5637 cells.

Lee SJ, Cho YH, Park K, Kim EJ, Jung KH, Park SS, Kim WJ, Moon SK.

Biochem Pharmacol. 2008 Jun 15;75(12):2289-300. Epub 2008 Apr 8.

PMID:: 18468578; [PubMed - indexed for MEDLINE]

Related citations

10.

Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants.

Brognard J, Dennis PA.

Cell Death Differ. 2002 Sep;9(9):893-904.

PMID:: 12181740; [PubMed - indexed for MEDLINE]

Related citations

11.

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA.

Biochim Biophys Acta. 2007 Aug;1773(8):1263-84. Epub 2006 Oct 7. Review.

PMID:: 17126425; [PubMed - indexed for MEDLINE]

Free PMC Article

Related citations

12.

Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.

Emaduddin M, Bicknell DC, Bodmer WF, Feller SM.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2358-62. Epub 2008 Feb 7.

PMID:: 18258742; [PubMed - indexed for MEDLINE]

Free PMC Article

Related citations

13.

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.

Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ.

Int J Cancer. 2009 Nov 15;125(10):2332-41.

PMID:: 19637312; [PubMed - indexed for MEDLINE]

Related citations

14.

Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

Tentler JJ, Nallapareddy S, Tan AC, Spreafico A, Pitts TM, Morelli MP, Selby HM, Kachaeva MI, Flanigan SA, Kulikowski GN, Leong S, Arcaroli JJ, Messersmith WA, Eckhardt SG.

Mol Cancer Ther. 2010 Dec;9(12):3351-62. Epub 2010 Oct 5.

PMID:: 20923857; [PubMed - indexed for MEDLINE]

Related citations

15.

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.

Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.

J Cell Physiol. 2009 Jul;220(1):214-21.

PMID:: 19288493; [PubMed - indexed for MEDLINE]

Related citations

16.

Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.

Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA.

Oncogene. 2007 Feb 8;26(6):813-21. Epub 2006 Aug 7.

PMID:: 16909118; [PubMed - indexed for MEDLINE]

Related citations

17.

Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade.

Lengyel E, Wang H, Gum R, Simon C, Wang Y, Boyd D.

Oncogene. 1997 May 29;14(21):2563-73.

PMID:: 9191056; [PubMed - indexed for MEDLINE]

Related citations

18.

Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.

Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Al-Kuraya KS.

Cancer Res. 2008 May 1;68(9):3379-88.

PMID:: 18451165; [PubMed - indexed for MEDLINE]

Related citations

19.

Final Report on Carcinogens Background Document for Formaldehyde.

National Toxicology Program.

Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.

PMID:: 20737003; [PubMed - as supplied by publisher]

Related citations

20.

Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells.

Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A, Albanell J.

Mol Cancer Ther. 2006 Mar;5(3):665-75. Erratum in: Mol Cancer Ther. 2006 May;5(5):1383.

PMID:: 16546981; [PubMed - indexed for MEDLINE]

Related citations

<< First< Prev

Page of 5

Supplemental Content

Filter your results:

Manage Filters

Find related data

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

You are here: NCBI > Literature > PubMed

Write to the Help Desk